[go: up one dir, main page]

UA117800C2 - Похідні урацилу або тиміну для лікування гепатиту с - Google Patents

Похідні урацилу або тиміну для лікування гепатиту с

Info

Publication number
UA117800C2
UA117800C2 UAA201302816A UAA201302816A UA117800C2 UA 117800 C2 UA117800 C2 UA 117800C2 UA A201302816 A UAA201302816 A UA A201302816A UA A201302816 A UAA201302816 A UA A201302816A UA 117800 C2 UA117800 C2 UA 117800C2
Authority
UA
Ukraine
Prior art keywords
compounds
salts
timin
uracyl
hepatitis
Prior art date
Application number
UAA201302816A
Other languages
English (en)
Inventor
Рольф Вагнер
Майкл Д. ТУФАНО
Кент Д. СТЮАРТ
Тодд У. Роквей
Джон Т. Рендольф
Джон К. Претт
Крістофер Е. Моттер
Клеренс Дж. Мейрінг
Кентон Л. Лондженекер
Йайа Ліу
Дейчунь Ліу
Аллен К. Крюгер
Уоррен М. Кейті
Дуглас К. Хатчінсон
Пеггі П. Хуанг
Чарльз А. Флентдж
Памела Л. Доннер
Девід А. Дегуй
Девід А. Бітебеннер
Девід М. Барнес
Шуанг ЧЕН
ІІ Тадіус С. Франчік
Йі Гао
Ентоні Р. Хайт
Джон І. Хенгевельд
Роджер Ф. Генрі
Брайєн Дж. Котекі
Сяочунь ЛОУ
Кеті Сарріс
Джефф Г. З. Жанг
Original Assignee
Еббві Айрленд Анлімітед Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117800(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Еббві Айрленд Анлімітед Компані filed Critical Еббві Айрленд Анлімітед Компані
Priority claimed from UAA201004147A external-priority patent/UA104995C2/uk
Publication of UA117800C2 publication Critical patent/UA117800C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Даний винахід належить до: (a) до сполук та їх солей, які, серед інших, інгібують HCV; (b) до проміжних сполук, придатних для одержання таких сполук та солей; (c) до композицій, що містять такі сполуки та солі; (d) до способів одержання таких проміжних сполук, сполук, солей та композицій; (e) до способів застосування таких сполук, солей та композицій; та (f) до наборів, що містять такі сполуки, солі та композиції.
UAA201302816A 2007-09-17 2008-09-17 Похідні урацилу або тиміну для лікування гепатиту с UA117800C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97287707P 2007-09-17 2007-09-17
US9679108P 2008-09-13 2008-09-13
UAA201004147A UA104995C2 (uk) 2007-09-17 2008-09-17 Похідні урацилу або тиміну для лікування гепатиту с

Publications (1)

Publication Number Publication Date
UA117800C2 true UA117800C2 (uk) 2018-10-10

Family

ID=39948002

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201302816A UA117800C2 (uk) 2007-09-17 2008-09-17 Похідні урацилу або тиміну для лікування гепатиту с

Country Status (30)

Country Link
US (3) US8415351B2 (uk)
EP (2) EP2725015A1 (uk)
JP (2) JP5734654B2 (uk)
KR (2) KR101660360B1 (uk)
CN (2) CN101801935B (uk)
AR (2) AR070027A1 (uk)
AU (1) AU2008302448B2 (uk)
BR (1) BRPI0816994B8 (uk)
CA (2) CA2699981C (uk)
CL (2) CL2008002794A1 (uk)
CO (1) CO6260076A2 (uk)
CR (2) CR11316A (uk)
DO (2) DOP2010000084A (uk)
ES (1) ES2453591T3 (uk)
GT (1) GT201000061A (uk)
IL (1) IL204547A (uk)
IN (1) IN2012DN05113A (uk)
MX (2) MX2010002905A (uk)
MY (1) MY162760A (uk)
NZ (3) NZ600371A (uk)
PA (1) PA8796201A1 (uk)
PE (2) PE20130209A1 (uk)
PH (1) PH12013500365A1 (uk)
RU (2) RU2543620C2 (uk)
SG (1) SG183733A1 (uk)
TW (2) TWI437994B (uk)
UA (1) UA117800C2 (uk)
UY (1) UY31344A1 (uk)
WO (1) WO2009039127A1 (uk)
ZA (2) ZA201204224B (uk)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2368882T3 (pl) 2007-09-17 2015-04-30 Abbvie Bahamas Ltd Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
RU2542099C2 (ru) * 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
CN101801935B (zh) * 2007-09-17 2014-12-03 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
CA2730517A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
MX2011002846A (es) 2008-09-26 2011-04-07 Hoffmann La Roche Derivados de pirina o pirazina para tratar el virus de la hepatitis c.
MX2011010049A (es) * 2009-03-24 2011-10-11 Abbott Lab Proceso para la preparacion de un compuesto antiviral.
WO2010111437A1 (en) * 2009-03-25 2010-09-30 Abbott Laboratories Antiviral compounds and uses thereof
EP2411007A4 (en) * 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF IRES-MEDIATED TRANSLATION
CN102448936A (zh) 2009-04-25 2012-05-09 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
SG176976A1 (en) * 2009-06-24 2012-02-28 Hoffmann La Roche Heterocyclic antiviral compound
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
EP2480533A1 (en) 2009-09-21 2012-08-01 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
MX2012005706A (es) * 2009-11-21 2012-06-12 Hoffmann La Roche Compuestos antivirales heterociclicos.
BR112012014299A2 (pt) * 2009-12-14 2016-07-05 Hoffmann La Roche composto de antivírus heterocíclicos
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
CA2801670A1 (en) 2010-07-07 2012-01-12 Leanna Renee Staben Heterocyclic antiviral compounds
WO2012009698A1 (en) 2010-07-16 2012-01-19 Abbott Laboratories Phosphine ligands for catalytic reactions
AU2015201698B2 (en) * 2010-07-16 2017-02-02 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
EP3415504A1 (en) * 2010-07-16 2018-12-19 AbbVie Ireland Unlimited Company Process for preparing antiviral compounds
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
WO2012020037A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US9248193B2 (en) 2011-03-18 2016-02-02 Abbvie Inc. Formulations of phenyl uracil compounds
CA2830324A1 (en) * 2011-03-31 2012-10-04 Konstanze Schafer Perfluorinated compounds for non-viral transfer of nucleic acids
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5734124B2 (ja) * 2011-07-21 2015-06-10 株式会社 東邦アーステック １，３−ジヨードヒダントイン類の製造方法
EP2740728A4 (en) 2011-08-01 2015-04-01 Sumitomo Dainippon Pharma Co Ltd URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201492007A1 (ru) 2012-05-15 2015-03-31 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
BR112014027584B1 (pt) 2012-05-15 2023-01-24 Novartis Ag Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
SG11201407152XA (en) 2012-05-15 2014-11-27 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2014004674A2 (en) 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
EP2887941B1 (en) 2012-08-21 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing antiviral compounds
SG11201503051QA (en) * 2012-10-18 2015-05-28 Abbvie Inc Formulations of pyrimidinedione derivative compounds
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
JP2016523924A (ja) 2013-07-02 2016-08-12 アッヴィ・インコーポレイテッド Ｈｃｖの治療方法
US9783509B2 (en) 2013-07-08 2017-10-10 Bayer Cropscience Aktiengesellschaft Six-membered C-N-linked aryl sulfide derivatives and aryl sulfoxide derivatives as pest conrol agents
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP3099295A1 (en) 2014-01-28 2016-12-07 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
JP6466461B2 (ja) 2014-02-03 2019-02-06 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Ｒｏｒガンマのジヒドロピロロピリジン阻害剤
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
WO2016016316A1 (en) 2014-08-01 2016-02-04 Nuevolution A/S Compounds active towards bromodomains
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
EP3207043B3 (en) 2014-10-14 2019-10-02 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2016196280A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Heterocycle-substituted bicyclic pesticides
JP2018525371A (ja) * 2015-07-30 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アリール置換された二環式ヘテロアリール化合物
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
JP6914257B2 (ja) 2015-11-20 2021-08-04 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのモジュレーター
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of rorϒ
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN107266373A (zh) * 2017-08-01 2017-10-20 安徽拜善晟制药有限公司 一种原料药达沙布韦的制备方法
US11613543B2 (en) 2018-03-26 2023-03-28 Novartis Ag Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
WO2021053495A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
NL9001075A (uk) 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
WO2001042225A2 (en) 1999-12-06 2001-06-14 F. Hoffmann-La Roche Ag 4-pyrimidinyl-n-acyl-l-phenylalanines
IL167957A (en) 2000-02-04 2009-07-20 Sumitomo Chemical Co Hydroxypyridine compounds
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JO2934B1 (en) * 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
PL2368882T3 (pl) * 2007-09-17 2015-04-30 Abbvie Bahamas Ltd Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
CN101801935B (zh) * 2007-09-17 2014-12-03 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
RU2542099C2 (ru) * 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
CA2730517A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
US8415351B2 (en) 2013-04-09
MX2010002905A (es) 2010-07-05
CR20150238A (es) 2015-07-01
AR070027A1 (es) 2010-03-10
RU2013104270A (ru) 2014-08-10
KR101660360B1 (ko) 2016-09-27
AR087472A2 (es) 2014-03-26
RU2599635C2 (ru) 2016-10-10
PE20130209A1 (es) 2013-03-24
ZA201204223B (en) 2015-12-23
CA2976793A1 (en) 2009-03-26
US20120213733A1 (en) 2012-08-23
JP2010539186A (ja) 2010-12-16
US20110070193A1 (en) 2011-03-24
AU2008302448B2 (en) 2014-11-06
BRPI0816994B1 (pt) 2019-12-24
IL204547A (en) 2016-04-21
JP2013049681A (ja) 2013-03-14
CR11316A (es) 2010-10-05
EP2725015A1 (en) 2014-04-30
MY162760A (en) 2017-07-14
TWI534137B (zh) 2016-05-21
CN101801935A (zh) 2010-08-11
UY31344A1 (es) 2009-04-30
SG183733A1 (en) 2012-09-27
CL2013000372A1 (es) 2013-10-04
PE20090705A1 (es) 2009-07-17
KR101552474B1 (ko) 2015-09-11
BRPI0816994B8 (pt) 2021-05-25
IN2012DN05113A (uk) 2015-10-23
CA2699981C (en) 2017-08-22
CN101801935B (zh) 2014-12-03
TWI437994B (zh) 2014-05-21
ES2453591T3 (es) 2014-04-08
NZ584720A (en) 2012-07-27
TW201443027A (zh) 2014-11-16
RU2543620C2 (ru) 2015-03-10
NZ618277A (en) 2015-07-31
EP2222646B1 (en) 2014-01-22
PA8796201A1 (es) 2009-04-23
EP2222646A1 (en) 2010-09-01
IL204547A0 (en) 2010-11-30
NZ600371A (en) 2014-07-25
CN102746239B (zh) 2016-02-10
DOP2010000084A (es) 2010-06-15
CL2008002794A1 (es) 2009-09-04
KR20150117632A (ko) 2015-10-20
KR20100068289A (ko) 2010-06-22
WO2009039127A1 (en) 2009-03-26
US9095590B2 (en) 2015-08-04
HK1147256A1 (en) 2011-08-05
RU2010114828A (ru) 2011-10-27
CO6260076A2 (es) 2011-03-22
GT201000061A (es) 2012-03-26
JP5734654B2 (ja) 2015-06-17
TW200918066A (en) 2009-05-01
US20140235638A1 (en) 2014-08-21
AU2008302448A1 (en) 2009-03-26
BRPI0816994A2 (pt) 2015-03-24
ZA201204224B (en) 2015-12-23
US8685991B2 (en) 2014-04-01
PH12013500365A1 (en) 2014-09-08
DOP2010000396A (es) 2013-12-31
MX338555B (es) 2016-04-20
CA2699981A1 (en) 2009-03-26
CN102746239A (zh) 2012-10-24

Similar Documents

Publication Publication Date Title
UA117800C2 (uk) Похідні урацилу або тиміну для лікування гепатиту с
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
HRP20070043A2 (hr) Antivirusna sredstva
CY1115893T1 (el) Anti-μολυσματικες πυριμιδινες και χρησεις αυτων
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
HRP20070078A2 (hr) Fosfonatni analozi spojeva koji inhibiraju hiv
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA200971074A1 (ru) Антивирусные соединения
EA201170772A1 (ru) Органические соединения
EA201200938A1 (ru) Производные имидазопиридина в качестве ингибиторов jak
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
EA200970156A1 (ru) Пиридизиноновые производные
MX2010009646A (es) Agentes terapeuticos antivirales.
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
ECSP088518A (es) Nucleósidos antivirales
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
GEP201706793B (en) Substituted nucleosides, nucleotides and analogs thereof
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
HRP20090076A2 (hr) Antivirusni fosfinatni spojevi
EA201190293A1 (ru) Пролекарства триптолида